Akoya biosciences and shanghai kr pharmtech announce chinese regulatory agency premarket approval for kr-ht5 in china to support next generation pathology clinical workflows

Marlborough, mass. and shanghai, china, may 02, 2024 (globe newswire) -- akoya biosciences, inc. (nasdaq: akya), the spatial biology company®, and shanghai kr pharmtech, a leading company providing molecular diagnostic solutions in china, have jointly announced that kr-ht5, which akoya biosciences co-developed with shanghai kr pharmtech utilizing the phenoimager ht technology as its foundation, has received premarket approval from china's national medical products administration (nmpa) to support next generation pathology clinical workflows.
AKYA Ratings Summary
AKYA Quant Ranking